X0202 SCHEDULE 13G 0001969280 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/30/2026 0001817229 Vor Biopharma Inc. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) TCG Crossover GP II, LLC b DE 0 2836539 0 2836539 2836539 N 5.2 OO These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 54,185,582 shares of Common Stock, as follows: (a) 48,847,504 shares of Common Stock outstanding as of March 23, 2026, as reported by the Issuer (as defined in Item 1(a) below) in its Annual Report on Form 10-K, filed with the United States Securities and Exchange Commission (the Commission) on March 30, 2026 (the Form 10-K), plus (b) 5,338,078 shares of Common Stock issued in an underwritten offering that closed on March 30, 2026, as reported in the Issuer's Current Report on Form 8-K, filed with the Commission on March 27, 2026 (the Offering). TCG Crossover Fund II, L.P. b DE 0 2836539 0 2836539 2836539 N 5.2 PN These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 54,185,582 shares of Common Stock, as follows: (a) 48,847,504 shares of Common Stock outstanding as of March 23, 2026, as reported by the Issuer in the Form 10-K, plus (b) 5,338,078 shares of Common Stock issued in the Offering. TCG Crossover GP III, LLC b DE 0 2836539 0 2836539 2836539 N 5.2 OO These securities are held of record by TCG Crossover III (as defined in Item 2(a) below). TCG Crossover GP III (as defined in Item 2(a) below) is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 54,185,582 shares of Common Stock, as follows: (a) 48,847,504 shares of Common Stock outstanding as of March 23, 2026, as reported by the Issuer in the Form 10-K, plus (b) 5,338,078 shares of Common Stock issued in the Offering. TCG Crossover Fund III, L.P. b DE 0 2836539 0 2836539 2836539 N 5.2 PN These securities are held of record by TCG Crossover III. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 54,185,582 shares of Common Stock, as follows: (a) 48,847,504 shares of Common Stock outstanding as of March 23, 2026, as reported by the Issuer in the Form 10-K, plus (b) 5,338,078 shares of Common Stock issued in the Offering. Chen Yu b X1 0 5673078 0 5673078 5673078 N 10.5 IN Consists of (i) 2,836,539 shares of Common Stock held of record by TCG Crossover II and (ii) 2,836,539 shares of Common Stock held of record by TCG Crossover III. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover II. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover III. Chen Yu is the sole managing member of each of TCG Crossover GP II and TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to the securities held of record by TCG Crossover II and TCG Crossover III. Based on 54,185,582 shares of Common Stock, as follows: (a) 48,847,504 shares of Common Stock outstanding as of March 23, 2026, as reported by the Issuer in the Form 10-K, plus (b) 5,338,078 shares of Common Stock issued in the Offering. Vor Biopharma Inc. 500 Boylston Street, Suite 1350, Boston, MA 02116 This joint statement on Schedule 13G is being filed by TCG Crossover Fund II, L.P. (TCG Crossover II), TCG Crossover GP II, LLC (TCG Crossover GP II), TCG Crossover Fund III, L.P. (TCG Crossover III) and TCG Crossover GP III, LLC (TCG Crossover GP III and together with TCG Crossover II, TCG Crossover GP II and TCG Crossover III, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein. The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301. TCG Crossover GP II and TCG Crossover GP II are each a limited liability company organized under the laws of the State of Delaware. TCG Crossover II and TCG Crossover III are each a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America. Y See Row 9 of the cover page for each Reporting Person and the corresponding comments. See Row 11 of the cover page for each Reporting Person and the corresponding comments. See Row 5 of the cover page for each Reporting Person and the corresponding comments. See Row 6 of the cover page for each Reporting Person and the corresponding comments. See Row 7 of the cover page for each Reporting Person and the corresponding comments. See Row 8 of the cover page for each Reporting Person and the corresponding comments. Y N Under certain circumstances set forth in the limited partnership agreements of TCG Crossover II and TCG Crossover III and the limited liability company agreements of TCG Crossover GP II and TCG Crossover GP III, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1: Joint Filing Agreement TCG Crossover GP II, LLC /s/ Craig Skaling 04/01/2026 TCG Crossover Fund II, L.P. /s/ Craig Skaling 04/01/2026 TCG Crossover GP III, LLC /s/ Craig Skaling 04/01/2026 TCG Crossover Fund III, L.P. /s/ Craig Skaling 04/01/2026 Chen Yu /s/ Craig Skaling 04/01/2026